Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals (CRVS) will participate in the 2026 Cantor Global Healthcare Conference in New York, NY, with leadership hosting one-on-one investor meetings and a fireside chat on September 10, 2026.
The fireside chat is scheduled for 1:00 pm ET (10:00 am PT). A live webcast, available via the company’s investor relations website, will remain accessible for 90 days after the event.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported peer‑reviewed final data in Blood from its Phase 1/1b trial of soquelitinib in T cell lymphoma, supporting its development in oncology and immune/inflammatory diseases, according to Corvus.
The study enrolled 75 heavily pre‑treated patients across multiple T cell lymphoma subtypes. Doses up to 600 mg twice daily were well tolerated with no dose‑limiting toxicities, significant adverse events, myelosuppression or immunosuppression. A 200 mg twice‑daily dose was chosen for expansion based on complete ITK target occupancy.
In the 200 mg cohort (N=36), patients with one to three prior therapies (N=24) achieved 9 objective responses (six complete, three partial), median progression‑free survival of 6.2 months, 30% progression‑free at 18 months, and median overall survival of 28.1 months with 67% alive at 24 months. Corvus highlighted a mechanism involving selective ITK inhibition, Th1 skewing and both tumor‑intrinsic and microenvironment effects.
Corvus is enrolling a registration Phase 3 trial in relapsed/refractory PTCL (150 patients) comparing soquelitinib to physician’s choice of belinostat or pralatrexate, with progression‑free survival as the primary endpoint. Soquelitinib has FDA Orphan Drug and Fast Track designations for T cell lymphoma and relapsed/refractory PTCL, respectively.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported a Q2 2026 net loss of $18.0 million versus $8.0 million a year earlier, driven mainly by higher soquelitinib clinical trial and personnel costs. Research and development expenses rose to $16.0 million from $7.9 million. Cash, cash equivalents and marketable securities were $215.2 million at June 30, 2026, including $189.4 million of net financing proceeds received in January, which Corvus expects will fund operations into the second quarter of 2028.
Corvus highlighted ongoing enrollment in its registrational Phase 3 relapsed/refractory PTCL trial and Phase 2 atopic dermatitis trial for soquelitinib, positive Phase 1 atopic dermatitis data presented at SID, continued ALPS collaboration with NIAID, and expanded collaboration with Angel Pharmaceuticals, including a $5.0 million equity investment.
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report its second quarter 2026 financial results.
According to Corvus Pharmaceuticals, domestic investors can join by dialing 1-800-717-1738, while international participants can use 1-646-307-1865 or an instant telephone access link. The live webcast will be available through the investor relations section of the company’s website, with a replay accessible for 90 days.
Corvus Pharmaceuticals (Nasdaq: CRVS) is investing $5 million in a new $13.5 million financing for Angel Pharmaceuticals, its China partner and largest equity holding. The funds are expected to support soquelitinib development in China for atopic dermatitis and asthma.
The financing backs Angel’s ongoing Phase 1b/2 atopic dermatitis trial and a planned Phase 2 asthma trial, with initial atopic dermatitis Phase 1b data anticipated in late 2026 and asthma trial initiation expected in early 2027.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami.
The Jefferies presentation is on June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is on June 8, 2026 at 11:20 AM ET. Live webcasts and 90-day replays will be available via Corvus' investor relations website.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported final Phase 1 data for oral ITK inhibitor soquelitinib in moderate-to-severe atopic dermatitis at the 2026 SID meeting.
The 72‑patient randomized, placebo-controlled trial showed dose-dependent efficacy, durable drug‑free disease control and biomarker changes consistent with increased persistent Treg cells and reduced Th2/Th17 activity, according to Corvus.
At 200 mg twice daily, up to 75% of patients achieved EASI 75 and no severe or serious adverse events occurred, with adverse events comparable to placebo. Corvus is enrolling the ~200‑patient SIERRA1 Phase 2 trial, while Angel Pharmaceuticals runs a related Phase 1b/2 study in China.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported Q1 2026 results and a business update on May 7, 2026. Key clinical advances include positive Phase 1 cohort 4 data for soquelitinib, Phase 2 initiation in atopic dermatitis, ongoing Phase 3 PTCL enrollment, and planned Phase 2 trials in hidradenitis suppurativa and asthma. Cash and marketable securities were $236.7M at March 31, 2026, expected to fund operations into Q2 2028.
Corvus Pharmaceuticals (Nasdaq: CRVS) appointed Andrew C. Chan, M.D., Ph.D., to its Board of Directors effective April 23, 2026. Dr. Chan brings 25 years of research leadership at Genentech, including Senior VP, Research Biology (2010–2025), and deep expertise in immunology and T cell signaling.
The addition is presented as strengthening scientific oversight as Corvus advances soquelitinib and its ITK inhibition platform across immune, inflammatory diseases, and cancer.
Corvus Pharmaceuticals (Nasdaq: CRVS) will host an in-person and virtual investor and analyst meeting on May 14, 2026 to highlight final Phase 1 soquelitinib data presented at the Society for Investigative Dermatology (SID) Annual Meeting.
Two oral presentations (one late-breaker) will detail immunologic and biomarker results and reports of prolonged drug-free remissions. The company will report Q1 2026 financial results on May 7, 2026; no conference call will accompany that release this quarter.